化疗联合改良供者淋巴细胞输注并阿扎胞苷维持治疗异基因造血干细胞移植术后复发患者长期缓解1例并文献复习
Long-Term Remission Achieved by Modified Donor Lymphocyte Infusion Combined with Chemotherapy and Azacitidine Maintenance Therapy in a Patient with Recurrence after Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report and Literature Review
DOI: 10.12677/acm.2024.143876, PDF,   
作者: 陶 昊, 种南南：山东第一医科大学(山东省医学科学院)研究生学院，山东 济南；董 琳*：山东第一医科大学第一附属医院血液科，山东 济南
关键词: 供者淋巴细胞输注；阿扎胞苷；造血干细胞移植；复发；Donor Lymphocyte Infusion； Azacitidine； Hematopoietic Stem Cell Transplantation； Recurrence
摘要: 供者淋巴细胞输注(donor lymphocyte infusion, DLI)通过诱导移植物抗白血病(GVL)作用，是目前治疗异基因造血干细胞移植(allo-HSCT)后复发患者有效的策略之一。本文报道了一例14岁CMML移植后血液学复发患者，接受了CAG方案(注射用盐酸阿柔比星、注射用盐酸阿糖胞苷、G-CSF)化疗后联合粒细胞集落刺激因子(G-CSF)动员的改良供者淋巴细胞输注(mDLI)治疗，并在MRD转阴后给予阿扎胞苷(AZA)维持治疗获得了长期缓解。
Abstract: Donor lymphocyte infusion (DLI) is one of the effective strategies for the treatment of relapsed patients after allogeneic hematopoietic stem cell transplantation (allo-HSCT) by inducing graft-versus-leukemia (GVL). This article reported a 14-year-old patient with hematological relapse after CMML transplantation. He received CAG regimen (aclarubicin hydrochloride for injection, cytarabine hydrochloride for injection, G-CSF) chemotherapy combined with granulocyte colony-stimulating factor (G-CSF) mobilization modified donor lymphocyte infusion (mDLI) treatment, and maintenance treatment with azacitidine (AZA) after MRD negative conversion achieved long-term remission.
文章引用：陶昊, 种南南, 董琳. 化疗联合改良供者淋巴细胞输注并阿扎胞苷维持治疗异基因造血干细胞移植术后复发患者长期缓解1例并文献复习[J]. 临床医学进展, 2024, 14(3): 1536-1543. https://doi.org/10.12677/acm.2024.143876

参考文献

[1] Guillaume, T., Malard, F., Magro, L., Labopin, M., Tabrizi, R., Borel, C., Chevallier, P., Vigouroux, S., Peterlin, P., Garnier, A., Rubio, M.T., Huynh, A., Milpied, N., Moreau, P., Gaugler, B., Yakoub-Agha, I. and Mohty, M. (2019) Prospective Phase II Study of Prophylactic Low-Dose Azacitidine and Donor Lymphocyte Infusions Following Allogeneic Hematopoietic Stem Cell Transplantation for High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome. Bone Marrow Transplantation, 54, 1815-1826. [Google Scholar] [CrossRef] [PubMed]
[2] Guillaume, T., ThÉPot, S., Peterlin, P., Ceballos, P., Bourgeois, A.L., Garnier, A., Orvain, C., Giltat, A., François, S., Bris, Y.L., Fronteau, C., Planche, L. and Chevallier, P. (2021) Prophylactic or Preemptive Low-Dose Azacitidine and Donor Lymphocyte Infusion to Prevent Disease Relapse Following Allogeneic Transplantation in Patients with High-Risk Acute Myelogenous Leukemia or Myelodysplastic Syndrome. Transplantation and Cellular Therapy, 27, 839.e1-839.e6. [Google Scholar] [CrossRef] [PubMed]
[3] Ramello, M.C., Benzaïd, I., Kuenzi, B.M., Lienlaf-Moreno, M., Kandell, W.M., Santiago, D.N., Pabon-Saldaña, M., Darville, L., Fang, B., Rix, U., Yoder, S., Berglund, A., Koomen, J.M., Haura, E.B. and Abate-Daga, D. (2019) An Immunoproteomic Approach to Characterize the CAR Interactome and Signalosome. Science Signaling, 12, Article eaap9777. [Google Scholar] [CrossRef] [PubMed]
[4] Schneidawind, C., Jahnke, S., Schober-Melms, I., Schumm, M., Handgretinger, R., Faul, C., Kanz, L., Bethge, W. and Schneidawind, D. (2019) G-CSF Administration Prior to Donor Lymphocyte Apheresis Promotes Anti-Leukaemic Effects in Allogeneic HCT Patients. British Journal of Haematology, 186, 60-71. [Google Scholar] [CrossRef] [PubMed]
[5] Fozza, C., Szydlo, R.M., Abdel-Rehim, M.M., Nadal, E., Goldman, J.M., Apperley, J.F. and Dazzi, F. (2007) Factors for Graft-versus-Host Disease after Donor Lymphocyte Infusions with an Escalating Dose Regimen: Lack of Association with Cell Dose. British Journal of Haematology, 136, 833-836. [Google Scholar] [CrossRef] [PubMed]
[6] 王昱, 黄晓军. 移植后恶性血液病的复发及处理[M]//黄晓军, 刘代红, 吴德沛. 实用造血干细胞移植. 北京: 人民卫生出版社, 2014: 408-420.
[7] Yang, L., Lai, X., Yang, T., Lu, Y., Liu, L., Shi, J., Zhao, Y., Wu, Y., Chen, Y., Yu, J., Xiao, H., Ouyang, G., Ren, J., Cao, J., Hu, Y., Tan, Y., Ye, Y., Cai, Z., Xu, W., Huang, H. and Luo, Y. (2024) Prophylactic versus Preemptive Modified Donor Lymphocyte Infusion for High-Risk Acute Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation: A Multicenter Retrospective Study. Bone Marrow Transplantation, 59, 85-92. [Google Scholar] [CrossRef] [PubMed]
[8] 中华医学会血液学分会干细胞应用学组. 中国异基因造血干细胞移植治疗血液系统疾病专家共识(II)——移植后白血病复发(2016年版). 中华血液学杂志, 2016, 37(10): 846-846. [Google Scholar] [CrossRef] 
[9] Deol, A. and Lum, L.G. (2010) Role of Donor Lymphocyte Infusions in Relapsed Hematological Malignancies after Stem Cell Transplantation Revisited. Cancer Treatment Reviews, 36, 528-538. [Google Scholar] [CrossRef] [PubMed]
[10] Frey, N.V. and Porter, D.L. (2008) Graft-versus-Host Disease after Donor Leukocyte Infusions: Presentation and Management. Best Practice & Research Clinical Haematology, 21, 205-222. [Google Scholar] [CrossRef] [PubMed]
[11] Soiffer, R.J., Alyea, E.P., Hochberg, E., Wu, C., Canning, C., Parikh, B., Zahrieh, D., Webb, I., Antin, J. and Ritz, J. (2002) Randomized Trial of CD8 T-Cell Depletion in the Prevention of Graft-versus-Host Disease Associated with Donor Lymphocyte Infusion. Biology of Blood and Marrow Transplantation, 8, 625-632. [Google Scholar] [CrossRef] [PubMed]
[12] Weissinger, E.M., Borchers, S., Silvani, A., Provasi, E., Radrizzani, M., Beckmann, I.K., Benati, C., Schmidtke, J., Kuehnau, W., Schweier, P., Luther, S., Fernandez-Munoz, I., Beutel, G., Ciceri, F., Bonini, C., Ganser, A., Hertenstein, B. and Stadler, M. (2015) Long Term Follow up of Patients after Allogeneic Stem Cell Transplantation and Transfusion of HSV-TK Transduced T-Cells. Frontiers in Pharmacology, 6, Article 76. [Google Scholar] [CrossRef] [PubMed]
[13] Wei, Y.Q., Cen, X.N., Liu, H.H., Sun, Y.H., Shi, Y.J., Liu, W., Dong, Y.J. and Ren, H.Y. (2017) Irradiation of Peripheral Blood Mononuclear Cells with 7.5 Gy X-Rays Prior to Donor Lymphocyte Infusion Inhibits Proliferation While Preserving Cytotoxicity, and Improves the Effectiveness of HSCT in Patients with Hematological Malignancies. Oncology Letters, 13, 4101-4108. [Google Scholar] [CrossRef] [PubMed]
[14] Lulla, P.D., Naik, S., Vasileiou, S., Tzannou, I., Watanabe, A., Kuvalekar, M., Lulla, S., Carrum, G., Ramos, C.A., Kamble, R., Hill, L., Randhawa, J., Gottschalk, S., Krance, R., Wang, T., Wu, M., Robertson, C., Gee, A.P., Chung, B., Grilley, B., Brenner, M.K., Heslop, H.E., Vera, J.F. and Leen, A.M. (2021) Clinical Effects of Administering Leukemia-Specific Donor T Cells to Patients with AML/MDS after Allogeneic Transplant. Blood, 137, 2585-2597. [Google Scholar] [CrossRef] [PubMed]
[15] Mo, X.D., Zhang, X.H., Xu, L.P., Wang, Y., Yan, C.H., Chen, H., Chen, Y.H., Han, W., Wang, F.R., Wang, J.Z., Liu, K.Y. and Huang, X.J. (2017) Comparison of Outcomes after Donor Lymphocyte Infusion with or without Prior Chemotherapy for Minimal Residual Disease in Acute Leukemia/Myelodysplastic Syndrome after Allogeneic Hematopoietic Stem Cell Transplantation. Annals of Hematology, 96, 829-838. [Google Scholar] [CrossRef] [PubMed]
[16] Tiribelli, M., Sperotto, A., Candoni, A., Simeone, E., Buttignol, S. and Fanin, R. (2009) Nilotinib and Donor Lymphocyte Infusion in the Treatment of Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph ALL) Relapsing after Allogeneic Stem Cell Transplantation and Resistant to Imatinib. Leukemia Research, 33, 174-177. [Google Scholar] [CrossRef] [PubMed]
[17] Botta, C., Caruso, N., Bossio, S., Storino, F., Console, G., Martino, M., Mendicino, F., Lucia, E., Morelli, R., Correale, P., Morabito, F., Gentile, M. and Vigna, E. (2020) Long-Term Remission Achieved by Ponatinib and Donor Lymphocytes Infusion in A Ph Acute Lymphoblastic Leukemia Patient in Molecular Relapse after Allogenic Stem Cell Transplant and Dasatinib: A Case Report. Frontiers in Oncology, 10, Article 967. [Google Scholar] [CrossRef] [PubMed]
[18] Claiborne, J., Bandyopathyay, D., Roberts, C., Hawks, K., Aziz, M., Simmons, G., Wiedl, C., Chung, H., Clark, W., McCarty, J. and Toor, A. (2019) Managing Post Allograft Relapse of Myeloid Neoplasms: Azacitidine and Donor Lymphocyte Infusions as Salvage Therapy. Leukemia & Lymphoma, 60, 2733-2743. [Google Scholar] [CrossRef] [PubMed]
[19] PoirÉ, X., Graux, C., Ory, A., Herman, J., Baron, F., Schoemans, H., Lewalle, P., De Becker, A., Deeren, D., Berneman, Z., Kerre, T., Zachee, P., Selleslag, D. and Beguin, Y. (2022) Sequential Administration of Low Dose 5-Azacytidine (AZA) and Donor Lymphocyte Infusion (DLI) for Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) in Relapse after Allogeneic Stem Cell Transplantation (SCT): A Prospective Study from the Belgian Hematology Society (BHS). Bone Marrow Transplantation, 57, 116-118. [Google Scholar] [CrossRef] [PubMed]
[20] Kalin, B., Van Norden, Y., Van Gelder, M., Breems, D., Maertens, J., Jongen-Lavrencic, M., Broers, A.E.C., Braakman, E., Grob, T., Zeijlemaker, W., Ossenkoppele, G.J., Meijer, E. and Cornelissen, J.J. (2020) Panobinostat and Decitabine Prior to Donor Lymphocyte Infusion in Allogeneic Stem Cell Transplantation. Blood Advances, 4, 4430-4437. [Google Scholar] [CrossRef] [PubMed]

为你推荐